The Treatment of Premature Infants With Brain Injury by Autologous Umbilical Cord Blood Stem Cells
The Treatment of Premature Infants With Brain Injury by Autologous Umbilical Cord Blood Stem Cells
To study the safety and effect of autologous umbilical cord blood stem cells for treatment brain injury
The purpose of this study is to evaluate the safety and effect of infusions of autologous (the patient's own)umbilical cord blood stem cells in newborn infants with hypoxic-ischemic encephalopathy. For this study, infants who have signs of moderate to severe encephalopathy at birth whose mothers have previously consented to providing cord blood stem cells for the Gunagdong Cord Blood Bank,or provided verbal consent for cord blood collection for the possibility of their baby's participation in this trial, can receive their own cord blood stem cells if an adequate number of cells that meet Guangdong Cord Blood Bank Quality standards are available in the first 14 postnatal days. Study activities also include serial blood draws concurrent with clinically indicated blood draws with a total volume of no more than 5 milliliters (1 teaspoon) from all study related tests. Babies will be followed for neurodevelopmental outcome at 4 - 6 and 9 - 12 months. MRI's will be obtained per clinical routine and results will be analyzed and described in study reports.
Inclusion Criteria:
Mothers must have consented for cord blood collection at delivery
cord blood must be available for extraction of stem cells.
->28 weeks gestation,<37weeks gestation
cord or neonatal pH<7.0 or base deficit>16 milliequivalents per liter (mEq/L) or history of acute perinatal event
either a 10 minute Apgar < 5 or continued need for ventilation.
All infants must have signs of encephalopathy within 6 hours of age.
Exclusion Criteria:
renzhx1990@163.com+8613538984634 ext. +86
Jjieyang0830@163.com39151777 ext. 020